


## Supplementary Figure S2



**Supplementary Figure S2. Dual CDK4/6-MEK inhibition synergistically suppresses the growth of some, but not all, MPNST PDXs in immune deficient mice.** The change in tumor volumes is shown for all xenograft tumors grown in immunodeficient mice. **(A)** S462 cell xenografts at the sciatic nerve of NSG mice were treated daily once tumors reached 250 mm<sup>3</sup> with vehicle, 12.5 mg/kg palbociclib (Palbo), 0.5 mg/kg mirdametininb (Mirda), or 12.5 mg/kg palbociclib plus 0.5 mg/kg mirdametininb combination (Combo). **Panels B-F**, PDXs from Johns Hopkins (JH) and Washington University at St. Louis (WU) were grown in the flank of female NRG mice. They were treated 5 days on/2 days off once tumors reached ~150 mm<sup>3</sup> with vehicle, 75 mg/kg ribociclib (Ribo), 0.075 mg/kg trametinib (Tram) except for 0.15 mg/kg in JH-2-079c, or the combination (Combo) for the indicated treatment periods. Error bars, SEM. *P* values were determined by simple linear regression to determine statistical differences between slopes (\*, *P* < 0.05; \*\*\*, *P* < 0.001).